Cellect Biotechnology Ltd. (APOP)

0.71
0.00 0.31
NASDAQ : Health Technology
Prev Close 0.71
Open 0.71
Day Low/High 0.66 / 0.71
52 Wk Low/High 0.61 / 7.80
Volume 62.37K
Avg Volume 285.70K
Exchange NASDAQ
Shares Outstanding 5.60M
Market Cap 3.97M
EPS -0.90
P/E Ratio 4.17
Div & Yield N.A. (N.A)

Latest News

Cellect Biotechnology Reports Fourth Quarter And Full Year 2018 Results And Recent Corporate Progress

Cellect Biotechnology Reports Fourth Quarter And Full Year 2018 Results And Recent Corporate Progress

Milestone Execution Positions the Company for Expedited Progress in 2019

Cellect Announces Positive Results From Cell2in Collaboration Showing Significant Improvement In Expansion Rate And Function Of Stem Cells

Cellect Announces Positive Results From Cell2in Collaboration Showing Significant Improvement In Expansion Rate And Function Of Stem Cells

Results and Validation of ApoGraft technology from a variety of sources could lead to a more cost-effective solution for the cell therapy industry.

Cellect Begins Collaboration With Washington University In Preparation For First U.S. Clinical Trial Using Cellect's ApoGraft™ For Bone Marrow Transplantations

Cellect Begins Collaboration With Washington University In Preparation For First U.S. Clinical Trial Using Cellect's ApoGraft™ For Bone Marrow Transplantations

The Collaboration will be led by Renowned Cell and Gene Therapy Experts Dr. John DiPersio and Dr. Mark Schroeder with Advisory support to Cellect by Prof. Negrin of Stanford and Dr. Cutler of Harvard Medical School

Completion Of Manufacturing Of Clinical Grade FasL Enables Cellect To Expedite U.S. Clinical Programs Into Multiple Studies

Completion Of Manufacturing Of Clinical Grade FasL Enables Cellect To Expedite U.S. Clinical Programs Into Multiple Studies

Supports Collaborations with Cell and Gene Therapy Companies

Cellect Biotechnology Reports Clinical And Regulatory Milestone Targets

Cellect Biotechnology Reports Clinical And Regulatory Milestone Targets

Recent FDA Hiring Decision Highlights Growing Importance of Cell and Gene Therapy Companies

Further To The Announcement Of The Agreement Signed With The South Korean Cell2in: KORIL Approves Cellect's Grant Application

Further To The Announcement Of The Agreement Signed With The South Korean Cell2in: KORIL Approves Cellect's Grant Application

The Korea-Israel Industrial R&D Foundation (KORIL-RDF) approves grant for the collaboration between Cellect and Cell2in, providing financing for the joint project

Lannett Scores FDA OK for Nexium Generic-Biotech Movers

Lannett Scores FDA OK for Nexium Generic-Biotech Movers

Cellect Biomd was up after securing orphan drug status for its transplant anti-rejection drug.

Dual-Listed Cellect To Voluntarily File For Delisting From Tel Aviv Stock Exchange

Company's Securities to Continue Trading Only on NASDAQ Stock Exchange in US

Cellect Receives Patent Notice Of Allowance From US Patent & Trademark Office Protecting Company's Technology In Multiple Key Indications

Cellect Receives Patent Notice Of Allowance From US Patent & Trademark Office Protecting Company's Technology In Multiple Key Indications

Method of treatment patent provides important protection in type I diabetes, inflammatory bowel disease, graft versus host disease and transplant rejection

Major Shareholder Buying Shares

Major Shareholder Buying Shares

Cellect Signs Agreement With The Hadassah Technological Transfer Company - Hadasit

Cellect Signs Agreement With The Hadassah Technological Transfer Company - Hadasit

Companies will test lowering transplant rejection symptoms using Cellect's ApoGraft method for stem cells selection

Cellect Biotechnology Ltd Provides Corporate Update And Reports Second Quarter 2016 Financial Results

Cellect Biotechnology Ltd Provides Corporate Update And Reports Second Quarter 2016 Financial Results

Raised Gross Proceeds of $8.4 Million through Pricing of July U.S. Initial Public Offering